Scholarlink

Introduction <p>Sarcopenia is a progressive skeletal muscle disorder prevalent among older adults and is associated with increased risk of disability, falls, and mortality. Although resistance training and adequate nutritional intake are well-supported by clinical evidence, their implementation is often limited by poor adherence and insufficient access to supervised interventions. This trial aims to evaluate the effectiveness of a real-time multicomponent remote rehabilitation program versus standard self-rehabilitation in older adults with sarcopenia.</p> Methods and analysis <p>This single-center, randomized, controlled, two-arm trial will be conducted at West China Hospital, Sichuan University. A total of 104 community-dwelling adults aged 60–75 years meeting the Asian Working Group for Sarcopenia (AWGS) diagnostic criteria will be randomly assigned (1:1) to either an intervention or a control group. The intervention group will receive personalized exercise and dietary guidance via a WeChat-based application with daily remote supervision from therapists. The control group will receive non-interactive, text- and image-based static dietary guidance and unsupervised exercise instructions. The primary outcome is knee extensor strength at 12 weeks, assessed using a dynamometer. Secondary outcomes include knee flexor strength, handgrip strength, 6-metre gait speed, Timed Up and Go Test (TUGT), 6-minute walk distance (6MWT), and appendicular skeletal muscle mass index (ASMI), and reversal of sarcopenia. Outcomes will be assessed at baseline, week 6, and week 12 by blinded assessors. Statistical analysis will be performed using R software (v4.4.0), with <i>P</i> &lt; 0.05 considered statistically significant.</p> Ethics and dissemination <p>This study was approved by the Ethics Committee of West China Hospital, Sichuan University, China (Approval No. 2024–2455). Results will be disseminated through peer-reviewed journals and academic conferences regardless of outcome direction.</p> Trial registration number <p>The trial is registered at ClinicalTrials.gov (registration number NCT06937073, April 2025).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-time multicomponent remote rehabilitation versus self-rehabilitation for sarcopenia: a randomized controlled trial protocol

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月25日

查看全文
  • Kexin Wang,
  • Linbo Peng,
  • Mingke You,
  • Bin Shen,
  • Jian Li

摘要

Introduction

Sarcopenia is a progressive skeletal muscle disorder prevalent among older adults and is associated with increased risk of disability, falls, and mortality. Although resistance training and adequate nutritional intake are well-supported by clinical evidence, their implementation is often limited by poor adherence and insufficient access to supervised interventions. This trial aims to evaluate the effectiveness of a real-time multicomponent remote rehabilitation program versus standard self-rehabilitation in older adults with sarcopenia.

Methods and analysis

This single-center, randomized, controlled, two-arm trial will be conducted at West China Hospital, Sichuan University. A total of 104 community-dwelling adults aged 60–75 years meeting the Asian Working Group for Sarcopenia (AWGS) diagnostic criteria will be randomly assigned (1:1) to either an intervention or a control group. The intervention group will receive personalized exercise and dietary guidance via a WeChat-based application with daily remote supervision from therapists. The control group will receive non-interactive, text- and image-based static dietary guidance and unsupervised exercise instructions. The primary outcome is knee extensor strength at 12 weeks, assessed using a dynamometer. Secondary outcomes include knee flexor strength, handgrip strength, 6-metre gait speed, Timed Up and Go Test (TUGT), 6-minute walk distance (6MWT), and appendicular skeletal muscle mass index (ASMI), and reversal of sarcopenia. Outcomes will be assessed at baseline, week 6, and week 12 by blinded assessors. Statistical analysis will be performed using R software (v4.4.0), with P < 0.05 considered statistically significant.

Ethics and dissemination

This study was approved by the Ethics Committee of West China Hospital, Sichuan University, China (Approval No. 2024–2455). Results will be disseminated through peer-reviewed journals and academic conferences regardless of outcome direction.

Trial registration number

The trial is registered at ClinicalTrials.gov (registration number NCT06937073, April 2025).